NICE Onpattro approval puts Alnylam back in hATTR running
NICE issued the drug a preliminary ‘no’, back in December 2018.
Read Moreby Anna Smith | Jul 9, 2019 | News | 0
NICE issued the drug a preliminary ‘no’, back in December 2018.
Read Moreby Anna Smith | May 24, 2019 | News | 0
The drug should be available for routine use within 90 days for patients in England.
Read Moreby Anna Smith | Apr 17, 2019 | News | 0
The decision will allow patients in England with the rare, inherited, severely debilitating and fatal disease to access the treatment on the NHS.
Read Moreby Selina McKee | Dec 12, 2018 | News | 0
The National Institute for Health and Care Excellence has issued draft guidelines rejecting NHS funding for two therapies that treat the rare inherited condition hereditary transthyretin-related amyliodsis (hATTR).
Read Moreby Selina McKee | Oct 8, 2018 | News | 0
Akcea and Ionis’ Tegsedi has won US approval for patients with hereditary transthyretin amyloidosis (hATTR), a rare disease causing build up of amyloid in the peripheral nervous system and multiple organs.
Read Moreby Selina McKee | Aug 31, 2018 | News | 0
Alnylam’s RNAi therapeutic Onpattro has been approved for use in Europe to treat Hereditary Transthyretin-Mediated (hATTR) Amyloidosis (hATTR amyloidosis) in adults with Stage 1 or Stage 2 polyneuropathy.
Read Moreby Selina McKee | Jul 17, 2018 | News | 0
European regulators have approved Akcea and Ionis’ Tegsedi for patients with hereditary transthyretin amyloidosis (hATTR), a rare disease causing build up of amyloid in the peripheral nervous system and multiple organs.
Read Moreby Selina McKee | Dec 20, 2017 | News | 0
Sanofi Genzyme and Alnylam Pharmaceuticals have submitted a marketing application to the European Medicines Agency for patisiran, an investigational RNAi therapeutic targeting transthyretin for the treatment of adults with hereditary transthyretin-mediated amyloidosis.
Read More





PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
